Calithera Biosciences Inc. (CALA) Trading Down 5.2%
Calithera Biosciences Inc. (NASDAQ:CALA)’s share price was down 5.2% during trading on Tuesday . The stock traded as low as $3.10 and last traded at $3.11, with a volume of 72,055 shares. The stock had previously closed at $3.28.
Several equities analysts recently commented on CALA shares. Wells Fargo & Co. reissued a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Finally, Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Calithera Biosciences currently has a consensus rating of “Buy” and an average target price of $10.38.
The stock’s 50-day moving average price is $3.33 and its 200 day moving average price is $4.80. The firm’s market cap is $63.73 million.
Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.03. On average, equities research analysts anticipate that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.